Background: Striae distensae are permanent dermal lesions that can cause significant psychosocial distress. A detailed understanding of the numerous treatment modalities available is essential to ensuring optimal patient outcomes.
S triae distensae (SD), also known as stretch marks, are common, permanent dermal lesions that can be symptomatic and are considered aesthetically undesirable; thus, they pose a significant psychosocial and therapeutic challenge. SD arise in areas of dermal stretching and most commonly occur on the abdomen, breasts, buttocks, and thighs. [1] [2] [3] Most literature has described SD during pregnancy (striae gravidarum) and puberty, with reported prevalences varying from 11% to 88%. 1, 2, [4] [5] [6] [7] Hormonal influences, [8] [9] [10] [11] [12] reduced genetic expression of fibronectin, collagen, and elastin, 13, 14 and mechanical stretching of the skin 2, [15] [16] [17] have all been postulated to contribute to SD formation. In the acute phase, SD appear as red/violaceous lesions (striae rubrae; SR) that can be raised and symptomatic. 18 The chronic form (striae albae; SA) exists as hypopigmented dermal depressions. 18, 19 Because of their high prevalence and impact on patients' quality of life, 20 there is great demand for an effective treatment. A vast array of treatment modalities have been investigated, ranging from topicals 19 and acid peel treatments 21 to more invasive methods such as laser therapy. 22 Although complete eradication of SD is not attainable, improving the appearance whilst reducing physical symptoms certainly is. It is therefore essential that clinicians managing SD have a detailed understanding of available treatment strategies to optimize patient outcomes and expectations.
We herein present a systematic review of SD, focusing on the different treatments and their proposed modes of action with outcomes, in relation to the histopathogenesis of the condition.
METHODS
Searches of both PubMed/ Medline and Scopus were conducted using the key words ''stretch marks,'' ''striae distensae,'' ''striae rubra,'' ''striae alba,'' and ''striae gravidarum'' AND ''management'' OR ''treatment.'' No limits were placed on publication date. Citations of articles were also reviewed. Exclusion criteria consisted of animal/ in vitro studies, noneEnglish language articles, unavailability of full text, book chapters, conference papers, letters, and reviews not specific to SD.
Data including treatment protocols, number of participants, and striae type were extracted. Relevant articles were assigned a level of evidence (LOE) independently by the authors, based on a quality rating scheme modified from the Oxford Centre for Evidence-Based Medicine for ratings of individual studies (Supplemental Table I ; available at http:// www.jaad.org). The risk of bias was assessed at both study and outcome levels.
RESULTS
Ninety-two articles of the 383 initially identified were included for analysis (Fig 1) . Seventy-four publications, representing 2328 patients, were relevant for quality assessment and assigned an LOE, the results of which are as follows: level 1, 15 (20.3%); level 2, 31 (41.8%); and level 4, 28 (37.8%).
Histopathogenesis
SD were first histologically described in 1889, 23 with SR and SA being histologically distinct from each other (Fig 2) . [24] [25] [26] [27] [28] [29] [30] [31] [32] They exhibit abnormalities in 3 core components of skin that normally provide it with tensile strength and elasticity: collagen, elastin, and fibrillin. [25] [26] [27] [28] [29] Early changes associated with SR include accumulation of degranulating mast cells and macrophages around mid-dermal elastic fibers, resulting in elastolysis. 24 These changes may be seen in macroscopically normal skin up to 3 cm away from the lesion. 24 As the striae progress to form SA, there is gradual epidermal atrophy with loss of rete ridges. 24, 25 Treatment Enhanced collagen production. The vast majority of treatments were targeted toward stimulating collagen production (Supplemental Table II ; available at http://www.jaad.org, and Fig 3) . Topicalagents. Tretinoin (retinoic acid) is believed to increase tissue collagen I levels through stimulation of fibroblasts 19, 33 and has inhibited activation of matrixdegrading enzymes after ultraviolet (UV)-induced skin damage, which implies that it may also protect the skin from other mechanisms of injury. 19 Numerous studies have investigated its efficacy (LOE 1, 2, 4), [33] [34] [35] [36] [37] with the majority suggesting that it can improve the appearance of early SD but not at lower doses. 35 However, study populations were small, and common side effects included transient erythema 19, 33, 34, 36, 37 and scaling of the skin. 19, 33, 34, 36 Centella asiatica is a plant used in Asian herbal medicine. It contains asiaticoside, which stimulates fibroblasts, with antagonistic effects on glucocorticoids also described. 38 Its use in the prevention of striae gravidarum has been investigated, with reported reductions in the development and severity of striae (LOE 1). 38 No side effects were observed. The use of Centella asiatica combined with boswellic acid, previously found to have anti-inflammatory effects, has also been tested. 39 Reductions in striae severity were noted; however, side effects included pruritus (LOE 4).
Hyaluronic acid is also thought to increase collagen production through stimulation of fibroblasts. 40 Two randomized, controlled trials (RCTs) (LOE 1) have reported improvements in the appearance of striae after its use, with a reported side effect being pain after treatment. 40, 41 No follow-up was conducted, and both incorporated subjective assessments of their outcome measures.
Chemical peel treatments. Chemical peel treatments involve the application of trichloroacetic acid or glycolic acid (GCA). They are thought to induce an initial inflammatory response, with subsequent increased collagen production. 21, 42 A nonrandomized, controlled trial investigating GCA
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reported decreases in striae furrow width but concluded that it may yield better results when used in combination with other products. 21 GCA combined with tretinoin and L-ascorbic acid 43 and trichloroacetic acid combined with the use of sand abrasion 42 or a postpeel cream 44 are such examples, all of which produced improvements in the appearance of striae. No RCTs have been performed (GCA: LOE 2; trichloroacetic acid: LOE 4), and postinflammatory hyperpigmentation (PIH) remains a concern.
42,44
Mechanical techniques. Aluminum oxide microdermabrasion mechanically ablates damaged skin. 45, 46 A study investigating its use in SD reported clinical improvements and increased type 1 procollagen formation (LOE 2). 46 Reported side effects included PIH.
Radiofrequency devices. Radiofrequency (RF) devices deliver RF current to the skin, which is converted to heat in the dermis as the result of its electrical resistance. 47, 48 After initial collagen denaturation with its use, there is subsequent increased collagen production. 48 The majority of trials investigating RF for the treatment of SD have reported clinical improvements (LOE 1, 2, 4). [47] [48] [49] [50] [51] [52] However, side effects include erythema and edema, 51,52 and the majority of trials had small cohorts.
49
Fractional lasers. Fractional lasers deliver microscopic beams of coherent and monochromatic light energy to the skin, creating areas of thermal damage termed microthermal zones, leading to increased dermal collagen production. Concerns surrounding PIH also remain. 18, 57, 61, 63 Fractional ablative carbon dioxide lasers have primarily been used in SA, with reported clinical improvements (LOE 2, 4). [65] [66] [67] [68] [69] Side effects include PIH. Gungor et al 70 compared the efficacy of an ablative erbium-yttrium aluminum garnet laser with a nonablative neodymium-doped yttrium aluminum garnet laser and found poor clinical results with both (LOE 2). The literature suggests that, when compared with nonablative lasers, ablative lasers are less well-tolerated and produce inconsistent results.
53
Diode laser. The 1450-nm diode laser is a nonfractional laser that has been shown to increase dermal collagen. 71 However, an RCT investigating its use in Fitzpatrick skin types IV-VI reported no improvements in SD but demonstrated high rates of PIH (LOE 1).
71
Intense pulsed light. Intense pulsed light consists of a broad-spectrum (515-1200 nm) visible beam of high-intensity light. 72 Studies investigating its use in SD have demonstrated increased dermal collagen levels after treatment (LOE 4). 72, 73 However, a study comparing intense pulsed light against a fractional carbon dioxide laser for the treatment of SD concluded that the laser was more effective (LOE 2). 74 No RCTs have yet been performed, and PIH remains a cause for concern.
72,74,75
Percutaneous collagen induction therapy. Percutaneous collagen induction therapy, or needling therapy, involves the creation of microclefts extending to the papillary dermis, resulting in increased production of collagen and elastin. 76, 77 Aust et al 76 reported improvements in skin texture and tightening after treatment (LOE 4). More recently, percutaneous collagen induction therapy compared favorably against microdermabrasion combined with sonophoresis 78 and against a carbon dioxide laser (LOE 2). 79 However, there are no RCTs, and side effects include erythema.
77-79
Platelet-rich plasma. Platelet-rich plasma (PRP) is a concentrated solution of autologous platelets containing growth factors and cytokines injected intradermally. 45 Ibrahim et al 45 investigated its use in SD with microdermabrasion, and, despite increased collagen levels after PRP treatment alone, 13% had worsening of their striae (LOE 2). They concluded that it is best to use PRP in combination 
Reduced vascularity
Vascular lasers. The 585-nm pulsed dye laser (PDL) is a commonly used vascular laser. Because of its high affinity for hemoglobin, which is present in the microvasculature of SR, it can reduce the erythema of these lesions (LOE 2).
85 Although improvements in both collagen 85, 86 and elastin 87 have been described after PDL treatment, these are probably subclinical, and PDL is likely to have minimal benefit in the treatment of SA (LOE 2, 4). 86, 88, 89 Care should be taken when using PDL with darker skin types (Fitzpatrick IV to VI) because melanin competes with hemoglobin for the light energy, which can result in PIH. 85, 90 Longo et al 91 tested the 577-nm copper bromide laser, which has higher rates of absorption by hemoglobin than its PDL counterpart; 33% had complete resolution of their SD, with the remainder showing a reduction in striae size (LOE 4). Crusting of the skin was a reported side effect. The neodymium-doped yttrium aluminum garnet vascular laser has also produced clinical improvements in SR (LOE 2,4); however, side effects include PIH 25, 60 (Supplemental Table III ; available at http:// www.jaad.org).
Increased melanin
UV light. A major aim for the treatment of SA is repigmentation of the lesion. Sadick et al 92 investigated the combined use of UVB (296-315 nm) and UVA1 (360-370 nm) light in 9 individuals. Despite all patients initially having [50% improvement in pigmentation, this improvement was only temporary, and side effects included transient hyperpigmentation (LOE 2) (Supplemental Table IV ; available at http://www.jaad.org).
Excimer laser. The xenon chloride excimer laser delivers narrow-band (308-nm) UVB radiation.
93 Its proposed advantages include being able to deliver the radiation quicker with increased precision, when compared with standard UV therapy. 93 Studies have reported improvements in striae pigmentation after its use (LOE 1, 4) . 93, 94 However, poor results were observed elsewhere (LOE 2), 95 and splaying of the pigment to involve surrounding skin is a reported side effect. 93, 95 A study investigating UVB light therapy and the xenon chloride excimer laser found that both cause hypertrophy and increased number of melanocytes, along with an increase in melanin, albeit not permanent.
96

Other treatments
Bio-Oil (Union Swiss Ltd, Cape Town, South Africa) consists of vitamins and plant extracts with an oil base. 97 One study investigating its use in SD demonstrated visual improvements after 2 weeks (LOE 2).
98
No side effects were reported (Supplemental Table IV ). 32 (B) Perivascular lymphocyte cuffing along with dermal edema and an increase in glycosaminoglycans are observed. 25 ,27,30,53 (C) Collagen fibers are stretched, aligned parallel to the dermal-epidermal junction, and a scanty lymphocytic infiltrate predominates. [25] [26] [27] [28] 32, 53 Cocoa butter is a natural fat and is used as a topical formulation to rehydrate the skin. 99 Two trials have investigated its use in preventing SD (LOE 1).
100,101
Both failed to show any significant benefits with its use.
Soltanipoor et al 102 and Taavoni et al 103 hypothesized that because of its high vitamin E content and moisturizing properties, olive oil could have a role in preventing striae gravidarum. However, no benefits with its use were reported (LOE 1).
Taşhan et al 104 studied the use of almond oil alone and with massage in preventing striae gravidarum formation and observed fewest striae in those applying almond oil with massage (LOE 2). However, an RCT comparing the effects of a topical cream (Saj, Seoidrood Co, Tehran, Iran) containing almond oil against olive oil found neither was effective at reducing the severity of striae gravidarum (LOE 1). 105 No side effects were reported in either trial.
Silicone gel has previously been used to improve scars, with promotion of skin hydration being one proposed mode of action 106 Ud-Din et al 106 investigated the effect of silicone against a placebo on SD. They demonstrated increased melanin and a reduction in hemoglobin and collagen with both silicone and placebo control gels. They concluded that the application of either gel by topical massage can improve SD (LOE 1). No side effects were reported.
DISCUSSION
SD are common yet undesirable permanent dermal lesions. Despite a basic understanding of the etiology and histopathologic changes that occur, finding an effective treatment is challenging. The majority of treatment modalities are targeted toward increasing collagen production. Topical treatments in this category still lack consistent high-quality LOEs, with the effects of massage potentially influencing the findings. Tretinoin has had variable outcomes, with its efficacy mostly demonstrated for the treatment of SR, and, despite both Centella asiatica and hyaluronic acid yielding promising results (Table I) , uncertainty remains regarding the type of striae they are most effective against. Chemical peel treatments, microdermabrasion, PRP, and percutaneous collagen induction therapy also lack highquality evidence, with no RCTs having yet been performed. Emerging techniques such as galvanopuncture appear to be promising; however, knowledge regarding its mode of action specific to SD is lacking, along with evidence-based trials. Lasers have been used in attempts to increase collagen production, reduce erythema in SR, and increase pigmentation in SA. Accurately interpreting the results of these studies is difficult, owing to the small sample sizes used and short follow-up periods. UV light has shown promise for the repigmentation of SA, although its lack of permanency means that Treatments for striae distensae (SD) and the highest level of evidence (LOE) available for their use. The majority of treatments are targeted toward enhancing collagen production. A large proportion of the randomized, controlled trials (RCTs) conducted have been with topical agents, producing varying results. GCA, Glycolic acid; IPL, intense pulsed light; Nd:YAG, neodymium-doped yttrium aluminum garnet; PCT, percutaneous collagen induction therapy; PDL, pulsed-dye laser; PRP, platelet-rich plasma; RF, radiofrequency; TCA, trichloroacetic acid; UV, ultraviolet; XeCl, xenon chloride.
repeated sessions are needed. Numerous other topicals, which mostly claim to hold moisturizing properties, are widely marketed despite the lack of evidence regarding their mode of action or efficacy.
Limitations
Exclusion criteria used may have resulted in relevant studies being missed, if, for example, they were not published in the English language. Of those included, making direct comparisons is extremely difficult, even for those using the same treatment modality, because of widely varying treatment protocols and differences in study populations. In addition, different outcome measures were used, of which none are yet validated. A large proportion assessed improvements through the use of clinical photographs, with differences in lighting potentially influencing results. Patient satisfaction scores were also widely used; however, one may question whether such scores would change if the treatments were not free or were provided outside the trial setting. Small sample sizes and limited follow-up periods are also major limitations in a large proportion of studies. Concerns surrounding publication bias also remain because the vast majority of papers reported some positive results.
CONCLUSIONS
Further RCTs are needed before definitive conclusions and recommendations can be made. Future work should focus on creating standardized outcome measures and treatment protocols to enable accurate comparisons between treatments.
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